PatientsVille.com Logo


Blister Medical Research Studies

Up-to-date List of Blister Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Blister Medical Research Studies

Rank Status Study
1 Recruiting Evaluation and Comparison of Keloids and Second Degree Burns Blisters Fluid
Conditions: Blisters;   Second Degree Burns;   Wounds
Outcome Measure: comparison of inflamation cells and proteins (proteomic evaluation) between Blisters caused by heat and Blisters caused by cryo injury
2 Recruiting An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin
Conditions: Breast Cancer;   Healthy Volunteer;   Prostate Cancer
Outcome Measures: To determine if cytokine levels in Blister fluid change following exposure of the skin to low or high dose radiation.;   To compare Blister fluid cytokine levels in Blister fluid from unirradiated skin in normal controls, breast cancer patients, and prostate cancer patients;   To determine if there are differences within circulating and skin proteome and cytokine patterns between participants with cancer and healthy normal controls;   To determine how proteomic pattern changes in skin correlate with circulating proteomic patterns.;   To determine if changes in the proteome in Blister fluid occur following exposure of the skin to low or high dose radiation.;   To evaluate the reproducibility of cytokine assays in simultaneously collected Blister fluid samples from normal patients.;   To determine how cytokine levels in skin correlate with circulating and urinary cytokine levels.;   To determine if cytokine levels and changes at the proteome level measured in Blister fluid correlate with absorbed radiation skin dose, acute RTOG skin toxicity (& gt; Grade 3), or late RTOG skin toxicity (& gt; Grade 2).
3 Recruiting Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)
Condition: Atherosclerosis
Intervention: Drug: Darapladib
Outcome Measures: Macrophage cell count and surface expression of markers of M1 and M2 polarization in Blister fluid;   Number of monocytes and surface expression of markers of M1 or M2 polarization in peripheral blood;   Enzymatic activity of Lp-PLA2 in Blister fluid;   Total cell count, lymphocyte count, neutrophil count and macrophage count in Blister fluid;   Concentrations of soluble mediators of macrophage polarization;   Time to healing of cantharidin-induced Blisters
4 Unknown  Subconjunctival Bevacizumab Effect on Bleb Vascularity
Conditions: Bleb Vascularity;   Bleb Fibrosis;   Trabeculectomy Failure
Intervention: Drug: Bevacizumab
Outcome Measures: Bleb vascularity grading;   Indiana Bleb Appearance Grading Scale (IBAGS);   Intra-ocular pressure;   Indication for subconjunctival Mitomycin C injection or revision of surgery = yes / no
5 Unknown  Comparison of Subconjunctival 5-Fluorouracil (FU) Injection and Mitomycin C for Treatment of Early Bleb Failure
Condition: Bleb
Intervention: Drug: 5-FU and Mitomycin
Outcome Measures: Iop and Bleb height,extent and vascularity;   complication of 5-FU injection or Mitomycin drop in treatment of early bleb failure
6 Recruiting DIVERT: Diversion of Flow in Intracranial VErtebral and Blood Blister-like Ruptured Aneurysms Trial: A Randomized Trial Comparing Pipeline Flow Diversion and Best-Standard-Treatment
Condition: Ruptured Aneurysm of Intracranial Artery
Interventions: Device: Flow Diversion;   Device: Best Standard Therapy
Outcome Measures: Neurological status of the patient;   Modified Rankin Scale score;   Successful PED FD deployment/aneurysm clip-ligation/aneurysm coiling, with patency of parent arteries;   Peri-operative complications;   Angiographic outcome;   Number of days of hospitalization;   Discharge disposition/location;   Any new stroke, neurological symptom or sign;   Hospital re-admission;   Hemorrhagic complications;   Re-treatment of the index aneurysm
7 Unknown  Treatment of Failing Blebs With Ranibizumab
Conditions: Glaucoma, Open-Angle;   Failing Bleb Following Trabeculectomy
Intervention: Drug: Ranibizumab (Lucentis)
Outcome Measure:
8 Not yet recruiting Prevention Trial Assessing Paper-Tape in Endurance Distances II (Pre-TAPED II)
Condition: Foot Friction Blister
Intervention: Device: Paper-Tape
Outcome Measure: occurrence of a foot Blister
9 Recruiting Visual Distraction as a Means of Enhancing Child Resistance
Condition: Unintentional Ingestion of Drugs Contained Within Prescription Vials and Blisters.
Intervention: Other: Visual distractor
Outcome Measures: Package selection;   Time to opening;   Time to selection (continuous variable);   Success/Failure to open
10 Not yet recruiting Clinical Trial to Evaluate Blister Graft Utilizing a Novel Harvesting Device for Treatment of Venous Leg Ulcers
Conditions: Impaired Wound Healing;   Venous Insufficiency of Leg;   Diabetic Ulcers
Intervention: Device: Harvesting Device (CelluTome©)
Outcome Measures: Time to healing in patients treated with epidermal grafting and standard of care vs. standard of care alone.;   Percentage of venous leg ulcers that have healed each week.;   Cost effectiveness of epidermal grafting versus standard of care.;   Incidence of adverse events with epidermal grafting versus standard of care.;   Correlation between protease level and healing rate.;   Pain scores as reported by subjects.
11 Recruiting Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus
Condition: Pemphigus
Intervention: Drug: Sirolimus (formerly known as Rapamycin)
Outcome Measures: Improvement of ABSIS Score while reducing Steroid Dosage;   Statistical Measures
12 Unknown  Study of Inflammatory Mechanisms in Epidermolysis Bullosa Simplex- Dowling Meara
Condition: Epidermolysis Bullosa Simplex Dowling Meara
Intervention: Procedure: Taking of liquid and top of Blisters
Outcome Measures: Markers of inflammation in epidermis in patients with severe DM-BS;   clinical characterization of DM-EBS Genotype-phenoty
13 Not yet recruiting Investigating Immune Mechanisms in Atopic Eczema
Condition: Atopic Dermatitis
Interventions: Procedure: Skin biopsy;   Procedure: Skin suction Blister;   Biological: Mantoux test
Outcome Measure: Number of regulatory T cells in lesional skin of atopic dermatitis patients compared to healthy volunteers
14 Unknown  Use of the Epidermal Micrografts for Wound Healing After Mohs or Excisional Surgery for Skin Cancer
Condition: Neoplasm of Skin
Intervention: Device: Momelan Technologies Epidermal Graft Harvesting System
Outcome Measures: Wound healing/scarring;   Incidence of adverse events;   Physician global satisfaction;   Subject global satisfaction
15 Unknown  Use of Epidermal Expansion System for Epidermal Grafting on Hypopigmented Skin and Surgical Wounds
Conditions: Surgical Wound;   Hypo-pigmented Skin
Intervention: Device: Momelan Technologies Epidermal Graft Harvesting System
Outcome Measures: Wound healing/pigmentation;   Patient Satisfaction;   Physician Satisfaction;   Incidence of adverse events
16 Recruiting Comparison of Immune Response in Normal Volunteers and Patients With Helminth Infections
Conditions: Healthy;   Helminthiasis
Outcome Measure:
17 Recruiting Inflammatory Responses in Normal Volunteers and Patients With Abnormal Immune Responses
Conditions: Healthy;   Inflammation;   Vasculitis
Outcome Measure:
18 Recruiting Nutrition Interventions to Support the Immune System in Response to Stress
Condition: Mitigation of Immune Function Decrements in Response to Stress
Interventions: Dietary Supplement: Immune-enhancing nutritional beverage;   Dietary Supplement: Probiotics (BB-12)
Outcome Measures: Skin barrier restoration;   Suction Blister cytokine response
19 Unknown  Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin
Condition: Epidermolysis Bullosa
Intervention: Drug: Oral erythromycin
Outcome Measures: number of patients with decrease of Blisters' number of at least 20% after 3 months of treatment by oral erythromycin;   Secondary end points are : effect of 3 months of oral erythromycin on - Global tolerance of treatment.;   Secondary end points are : effect of 3 months of oral erythromycin on - Involved area;   Secondary end points are : effect of 3 months of oral erythromycin on - pruritus,
20 Recruiting Bronchoscopic Intrabullous Autologous Blood Instillation (BIABI) for Emphysema
Condition: Bullous Emphysema
Intervention: Procedure: Bronchoscopic intrabullous autologous blood instillation
Outcome Measures: Change in the Residual Volume (RV) following treatment;   Change in TLC 6 months following treatment;   Change in RV/TLC ratio 6 months following treatment;   Changes in FEV1 and FVC 6 months following treatment;   Change in the intrathoracic gas volume 6 months following treatment;   Change in DLCOc 6 months following treatment;   Change in the SGRQ score 6 months following treatment;   Change in the mMRC score 6 months following treatment;   Change in the 6MWD 6 months following treatment;   Change in CT measured lung volumes 6 months following treatment;   Adverse events

These studies may lead to new treatments and are adding insight into Blister etiology and treatment.

A major focus of Blister research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Blister